Effects of PVC chemotherapy on advanced transitional cell carcinoma
Author Information
Author(s): Mulatero C, McClaren B R, Mason M, Oliver R T D, Gallagher C J
Primary Institution: Dept. of Medical Oncology, St Bartholomew's Hospital, London
Hypothesis
The study evaluates the efficacy and toxicity of the combination of vinblastine, paclitaxel, and cisplatin in treating advanced transitional cell carcinoma.
Conclusion
The PVC regimen was found to be less effective and less toxic than expected, suggesting an inhibitory interaction between vinblastine and paclitaxel.
Supporting Evidence
- The overall response rate was 46%.
- Neutropenia at Grade 3–4 occurred in 21% of cycles.
- Median time to progression was 6 months.
- Median survival was 11 months.
Takeaway
Doctors tested a mix of three cancer drugs on patients with a specific type of bladder cancer, but it didn't work as well as they hoped.
Methodology
Patients received a specific combination of chemotherapy drugs over a set schedule, with adjustments based on their health.
Limitations
The study had a small sample size and responses were only observed in patients with locally recurrent tumors.
Participant Demographics
15 patients (13 men, 2 women) with a median age of 66 years.
Statistical Information
Confidence Interval
95% CI 2–40% for complete responses; 95% CI 12–62% for partial responses; 95% CI 21–73% for overall response rate.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website